Delta 9 Receives Extract Sales Authorization from Health Canada
WINNIPEG, Manitoba, Dec. 06, 2019 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce that on December 4, 2019 it received an updated processing license from Health Canada. The license authorizes Delta 9 to sell cannabis extracts, cannabis topicals, and edible cannabis products as defined under the Cannabis Regulations (Canada). This development, following the Company’s submission to Health Canada of new product notifications for nine (9) new derivative cannabis products on November 5, 2019, means the Company will be authorized to begin sales of cannabis extracts on January 5, 2020
“This is an exciting milestone for us,” said John Arbuthnot, CEO of Delta 9, “Our team has worked tirelessly toward our initial rollout of vaporizable oil cartridges, disposable vape oil pens, and dried cannabis extracts. We plan to begin shipments of these products early in the new year.”
Extract Product Portfolio
Dried Sift Cannabis
The Company is currently developing its “Sapphire” line of dried sift cannabis products for the recreational cannabis market which involves sifting the Company’s blended products and refining them, leaving more of the high potency resin glands and less of the low potency plant material. The final product is a yellow/brownish powder and has a potency that is up to triple that of the whole flower dried cannabis materials. The Company plans to release dried sift products in the recreational cannabis market in the first quarter of 2020. Management expects that retail pricing for these products will be up to $25 per gram.
Vaporizable Cannabis Oils
The Company is currently working with Westleaf Inc. (“Westleaf”) through its subsidiary Westleaf Labs LP to develop a line of vaporizable cannabis oil products including a line of vaporizable oil cartridges and a line of disposable vape pens. The products, which will be branded as “Harmony”, “Cruise”, and “Blast”, will contain distilled cannabis oil and cannabis terpenes, in varying concentrations of active cannabinoids. The Company plans to release the vape products in the recreational cannabis market in the first quarter of 2020.
Nanosphere Evolve Products
Delta 9 has acquired an exclusive license in Canada to manufacture and sell products made with the patented technology of Nanosphere Health Sciences Inc. (“NanoSphere”) for the delivery of cannabinoids via nanoparticle technology. The two companies are in the process of developing the first product for Canada; an intraoral cannabis oil containing cannabinoid nanoparticles.
The NanoSphere delivery system for cannabis works by nano-encapsulating active ingredients in phospholipid membranes for transportation through the skin and mucosa into the bloodstream within minutes. Cannabis applications of the technology include transdermal viscous gels, intranasal products and intraoral products, all of which provide rapid results, precise dosages and high bioavailability. The NanoSphere delivery system of cannabis can eliminate the need for inhalation or ingestion of cannabis, offering users a potentially safer and more effective method of consumption.
For more information contact:
Investor & Media Contact:
Ian Chadsey VP Corporate Affairs
Mobile: 204-898-7722
E-mail:
About Delta 9 Cannabis Inc.
Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9's shares trade on the Toronto Stock Exchange under the symbol "DN" and on the OTCQX under the symbol VRNDF. For more information, please visit .
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) Delta 9’s plans to expand its cannabis product offerings; and (ii) Health Canada approvals for certain cannabis products. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including failure to receive all necessary approvals for new cannabis product offerings or new cannabis product offerings not being developed by Delta 9, as well as all risk factors set forth in the annual information form of Delta 9 dated April 30, 2019 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
